Long-term follow-up of type II membranoproliferative glomerulonephritis in two children

Area of Science:

• Nephrology
• Immunology

Background:

• Type II membranoproliferative glomerulonephritis (MPGN) is often associated with poor prognosis and progression to end-stage renal failure.
• Treatment options for MPGN are limited, and long-term outcomes are frequently unfavorable.

Observation:

• This study presents the long-term follow-up of two patients diagnosed with type II MPGN.
• One patient received high-dose alternate-day prednisolone, while the other was treated with dipyridamole.
• Both patients demonstrated favorable clinical courses over extended follow-up periods of 8.5 and 15.5 years.

Findings:

• The patient treated with prednisolone experienced resolution of urinary abnormalities within 2 years, with subsequent histological improvement noted on follow-up renal biopsies.
• The patient treated with dipyridamole showed persistent, albeit mild, histological changes on biopsy after 6 years, with normalization of urine occurring 14 years after disease onset.
• Intramembranous electron-dense deposits remained present in both patients throughout the observation periods (7 and 6 years, respectively).

Implications:

• These findings suggest that a subset of patients with type II MPGN may exhibit a favorable clinical course, potentially influenced by specific therapeutic interventions.
• The study highlights the possibility of long-term remission and histological improvement in select MPGN cases, challenging the notion of universally poor outcomes.
• Further research into identifying predictors of favorable responses and optimizing treatment strategies for type II MPGN is warranted.